Nomura Increases Alexion Pharmaceuticals (ALXN) Price Target to $165.00

Alexion Pharmaceuticals (NASDAQ:ALXN) had its price target boosted by Nomura to $165.00 in a research report released on Thursday. Nomura currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Evercore ISI raised Alexion Pharmaceuticals from an in-line rating to an outperform rating in a report on Monday, February 5th. Citigroup reduced their price target on Alexion Pharmaceuticals from $173.00 to $170.00 and set a buy rating for the company in a report on Friday, February 9th. BMO Capital Markets raised their price target on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an outperform rating in a report on Friday, February 9th. Leerink Swann reduced their price target on Alexion Pharmaceuticals from $166.00 to $153.00 and set an outperform rating for the company in a report on Friday, February 9th. Finally, Stifel Nicolaus reissued a buy rating and issued a $151.00 price target on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and twenty have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $155.95.

Shares of ALXN traded up $0.56 during mid-day trading on Thursday, hitting $111.85. The company’s stock had a trading volume of 413,059 shares, compared to its average volume of 2,160,640. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. The stock has a market capitalization of $24,635.08, a P/E ratio of 21.59, a P/E/G ratio of 1.04 and a beta of 1.13. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34.



Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.09 by $0.39. The business had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm earned $1.26 EPS. research analysts anticipate that Alexion Pharmaceuticals will post 6.12 EPS for the current year.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 13,245 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the completion of the transaction, the chief executive officer now owns 131,425 shares of the company’s stock, valued at $15,286,041.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Heidi L. Wagner sold 655 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the transaction, the senior vice president now directly owns 32,635 shares of the company’s stock, valued at approximately $3,826,780.10. The disclosure for this sale can be found here. Insiders sold a total of 28,700 shares of company stock valued at $3,345,708 over the last ninety days. 4.35% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Factory Mutual Insurance Co. increased its position in Alexion Pharmaceuticals by 104.5% during the fourth quarter. Factory Mutual Insurance Co. now owns 358,500 shares of the biopharmaceutical company’s stock worth $42,873,000 after buying an additional 183,200 shares in the last quarter. Creative Planning increased its position in Alexion Pharmaceuticals by 72.2% during the fourth quarter. Creative Planning now owns 27,773 shares of the biopharmaceutical company’s stock worth $3,321,000 after buying an additional 11,642 shares in the last quarter. Boston Advisors LLC increased its position in Alexion Pharmaceuticals by 3.0% during the fourth quarter. Boston Advisors LLC now owns 149,241 shares of the biopharmaceutical company’s stock worth $17,848,000 after buying an additional 4,315 shares in the last quarter. Twin Capital Management Inc. increased its position in Alexion Pharmaceuticals by 26.5% during the fourth quarter. Twin Capital Management Inc. now owns 38,786 shares of the biopharmaceutical company’s stock worth $4,638,000 after buying an additional 8,136 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Alexion Pharmaceuticals by 3.9% during the fourth quarter. Rhumbline Advisers now owns 403,489 shares of the biopharmaceutical company’s stock worth $48,253,000 after buying an additional 15,174 shares in the last quarter. 95.07% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Nomura Increases Alexion Pharmaceuticals (ALXN) Price Target to $165.00” was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://dakotafinancialnews.com/2018/04/13/nomura-increases-alexion-pharmaceuticals-alxn-price-target-to-165-00.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply